They also gave press coverage about the company a news buzz of 0.0 out of 10, indicating that recent news coverage is extremely unlikely to have an impact on the company's share price in the near future. It operates through two segments, Generic Medicines and Specialty Medicines. During the same quarter last year, the firm earned $0.60 earnings per share.
Find the latest Teva Pharmaceutical Industries (TEVA) stock quote, history, news and other vital information to help you with your stock trading and investing. Teva Pharmaceutical Industries has received a consensus rating of Hold. There are currently 4 sell ratings, 12 hold ratings and 6 buy ratings for the stock, resulting in a consensus recommendation of "Hold." Learn everything you need to know about successful options trading with this three-part video course.Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools:You have already added five stocks to your watchlist. TEVA stock was sold by a variety of institutional investors in the last quarter, including Psagot Investment House Ltd., Personal Resources Investment & Strategic Management Inc., Mivtachim The Workers Social Insurance Fund Ltd. Teva Pharmaceutical Industries Ltd (NYSE:TEVA) posted its quarterly earnings results on Thursday, May, 2nd. Some companies that are related to Teva Pharmaceutical Industries include Based on aggregate information from My MarketBeat watchlists, some companies that other Teva Pharmaceutical Industries investors own include Teva Pharmaceutical Industries trades on the New York Stock Exchange (NYSE) under the ticker symbol "TEVA. Interested parties can register for or listen to the call using Teva Pharmaceutical Industries Ltd (NYSE:TEVA) released its quarterly earnings results on Thursday, May, 7th.
22 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Teva Pharmaceutical Industries in the last year. Want to see which stocks are moving? Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.Get daily stock ideas top-performing Wall Street analysts. Stock analysis for Teva Pharmaceutical Industries Ltd (TEVA:New York) including stock price, stock chart, company news, key statistics, fundamentals and company profile. The firm ranks coverage of companies on a scale of negative five to five, with scores nearest to five being the most favorable. Offering traders deep liquidity across listed option contracts. TEVA: Get the latest Teva Pharmaceutical Industries stock price and detailed information including TEVA news, historical charts and realtime prices. Please log in to your account or sign up in order to add this asset to your watchlist. High institutional ownership can be a signal of strong market trust in this company.Earnings for Teva Pharmaceutical Industries are expected to grow by 5.42% in the coming year, from $2.40 to $2.53 per share.The P/E ratio of Teva Pharmaceutical Industries is -16.14, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.The P/E ratio of Teva Pharmaceutical Industries is -16.14, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Teva Pharmaceutical Industries has a PEG Ratio of 0.82. The company reported $0.57 earnings per share for the quarter, topping the Zacks' consensus estimate of $0.55 by $0.02. Combining the high performance of NYSE Pillar technology with a taker/maker fee schedule. Get short term trading ideas from the MarketBeat Idea Engine. Teva Pharmaceutical Industries issued an update on its FY20 earnings guidance on Thursday, May, 7th. The company's revenue was up 5.0% compared to the same quarter last year. The business earned $4.30 billion during the quarter, compared to the consensus estimate of $4.38 billion. Teva stock price target raised to $16 from $11 at SunTrust RH Jun. NYSE American Options. ET by Tomi Kilgore Teva Pharmaceuticals upgraded to buy from hold at SunTrust RH The company issued revenue guidance of $16.6-17.0 billion, compared to the consensus revenue estimate of $16.74 billion.22 brokers have issued 12-month price targets for Teva Pharmaceutical Industries' shares.
Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Teva Pharmaceutical Industries Ltd (NYSE:TEVA) Expected to Post Quarterly Sales of $3.90 Billion www.americanbankingnews.com - July 15 at 2:00 AM $0.51 Earnings Per Share Expected for Teva Pharmaceutical Industries Ltd (NYSE:TEVA) This Quarter
The research firm scores the sentiment of news coverage by reviewing more than six thousand news and blog sources in real time. Teva Pharmaceutical Industries Limited, a pharmaceutical company, develops, manufactures, markets, and distributes generic medicines and a portfolio of specialty medicines worldwide. On average, they anticipate Teva Pharmaceutical Industries' stock price to reach $11.67 in the next twelve months. The firm earned $4.36 billion during the quarter, compared to the consensus estimate of $4.15 billion. The Specialty Medicines segment provides specialty medicines for use in central nervous system and respiratory indications. Teva Pharmaceutical Industries employs 40,039 workers across the globe.The official website for Teva Pharmaceutical Industries is Teva Pharmaceutical Industries' mailing address is 5 BAZEL ST P O B 3190, PETACH TIKVA L3, 49131.